Vontobel Holding Ltd. Sells 878 Shares of GSK plc (NYSE:GSK)

Vontobel Holding Ltd. lessened its stake in GSK plc (NYSE:GSK) by 6.3% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 13,075 shares of the pharmaceutical company’s stock after selling 878 shares during the period. Vontobel Holding Ltd.’s holdings in GSK were worth $485,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of GSK. Dynamic Advisor Solutions LLC raised its position in GSK by 25.5% in the 3rd quarter. Dynamic Advisor Solutions LLC now owns 7,152 shares of the pharmaceutical company’s stock worth $259,000 after purchasing an additional 1,453 shares during the last quarter. IFP Advisors Inc raised its position in GSK by 22.9% in the 3rd quarter. IFP Advisors Inc now owns 7,035 shares of the pharmaceutical company’s stock worth $255,000 after purchasing an additional 1,312 shares during the last quarter. Advisors Management Group Inc. ADV raised its position in GSK by 2.1% in the 3rd quarter. Advisors Management Group Inc. ADV now owns 82,516 shares of the pharmaceutical company’s stock worth $2,991,000 after purchasing an additional 1,686 shares during the last quarter. Alhambra Investment Partners LLC raised its position in GSK by 2.9% in the 3rd quarter. Alhambra Investment Partners LLC now owns 15,255 shares of the pharmaceutical company’s stock worth $553,000 after purchasing an additional 432 shares during the last quarter. Finally, Roberts Wealth Advisors LLC raised its position in GSK by 4.6% in the 3rd quarter. Roberts Wealth Advisors LLC now owns 71,117 shares of the pharmaceutical company’s stock worth $2,601,000 after purchasing an additional 3,125 shares during the last quarter. Institutional investors own 15.74% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have commented on the stock. Jefferies Financial Group raised shares of GSK from a “hold” rating to a “buy” rating in a report on Wednesday, January 3rd. Guggenheim raised shares of GSK from a “neutral” rating to a “buy” rating in a report on Monday, March 4th. Citigroup raised shares of GSK from a “neutral” rating to a “buy” rating in a report on Tuesday, February 13th. Finally, Morgan Stanley assumed coverage on shares of GSK in a report on Tuesday, January 23rd. They set an “equal weight” rating for the company. One analyst has rated the stock with a sell rating, one has given a hold rating, three have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy”.

GSK Price Performance

Shares of GSK stock opened at $40.60 on Tuesday. GSK plc has a 12-month low of $33.33 and a 12-month high of $43.84. The firm has a market capitalization of $84.14 billion, a price-to-earnings ratio of 13.49, a price-to-earnings-growth ratio of 1.40 and a beta of 0.64. The company has a quick ratio of 0.62, a current ratio of 0.88 and a debt-to-equity ratio of 1.19. The firm has a fifty day moving average of $41.88 and a 200-day moving average of $38.86.

GSK (NYSE:GSK) last announced its quarterly earnings results on Wednesday, January 31st. The pharmaceutical company reported $0.72 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.76 by ($0.04). GSK had a net margin of 16.24% and a return on equity of 51.45%. The firm had revenue of $10 billion during the quarter, compared to analyst estimates of $9.79 billion. On average, equities research analysts forecast that GSK plc will post 4.03 earnings per share for the current year.

GSK Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Thursday, April 11th. Stockholders of record on Friday, February 23rd were issued a $0.3564 dividend. This is a positive change from GSK’s previous quarterly dividend of $0.34. The ex-dividend date was Thursday, February 22nd. This represents a $1.43 annualized dividend and a dividend yield of 3.51%. GSK’s payout ratio is 52.82%.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.